Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis

BACKGROUND: Landmark trials have established the benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) in cardiovascular disease including heart failure with reduced and preserved ejection fraction and renal diseases regardless of the presence of diabetes mellitus. However, studies evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Olagunju, Abdulbaril, Yamani, Naser, Kenny, Dorothy, Mookadam, Martina, Mookadam, Farouk, Unzek, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724001/
https://www.ncbi.nlm.nih.gov/pubmed/36483765
http://dx.doi.org/10.4330/wjc.v14.i11.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724001/
https://www.ncbi.nlm.nih.gov/pubmed/36483765
http://dx.doi.org/10.4330/wjc.v14.i11.599

Ejemplares similares